<DOC>
	<DOC>NCT02887976</DOC>
	<brief_summary>An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.</brief_summary>
	<brief_title>Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201</brief_title>
	<detailed_description>An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201. An exploratory endpoint of Improved safety from switching from Zytiga (aberaterone Acetate 1000mg(4 x 250 mg qd) to SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) will also be ascertained..</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1. Written informed consent obtained prior to any studyrelated procedure being performed 2. Previous, uninterrupted enrollment and treatment in trial number CHLAA201. 1. Progressive disease as ascertained by the investigator using standardofcare evaluations. 2. CHLAA201 D84 blood counts of the following: 1. Absolute neutrophil count &gt; 1500/µL 2. Platelets &gt; 100,000/µL 3. Hemoglobin &gt; 9 g/dL 3. CHLAA201 D84 chemistry values of the following: 1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x Upper Limit of Normal (ULN) 2. Total bilirubin &lt; 1.5 x ULN 3. Creatinine&lt; 1.5 x ULN 4. Albumin &gt; 3.0 g/dL 5. Potassium &gt; 3.5 mmol/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castrate Resistant Prostate Cancer (CRPC)</keyword>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
</DOC>